leadXpro, a spin-off company of PSI active in the field of biotechnology, and Golgi Neurosciences, a biotech incubator based in Milan, have announced a partnership to develop therapies for neurodegenerative diseases. They are working on positive and negative modulators of the GPR65 receptor, which plays a role in neuroinflammation, multiple sclerosis, Parkinson's disease, fibrosis, cancer, and inflammatory bowel disease.